olivLaw · US equity research
Innospec Inc. IOSP
Chemicals & Allied Products · SIC 2800 · Vertical: Chemicals & Allied Products (SIC 2800)
Innospec is an international specialty chemicals company with three segments: Performance Chemicals, Fuel Specialties and Oilfield Services. In the second quarter of 2026 total revenues rose 12 percent, and the company remains debt-free with cash of over 250 million dollars, giving it flexibility in an uneven market.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Innospec Inc. (IOSP) stock was 80.65 USD (−18.72% on the day), with market capitalisation 2.0 bn USD, P/E 14.2 on diluted EPS of 5.67 USD over the last 12 months, dividend yield 2.12%, beta 0.70, 52-week range 65.89–101.41 USD. Latest reported quarter (Q3 2026): revenue of 473.6 m USD (+7.2% YoY), net income of 31.8 m USD (+146.5% YoY), diluted EPS 1.29 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 19.4
- oversold (≤ 30)
- Bollinger (20, 2)
- 89.22 – 105.94
- below the lower band · %B -0.51 · band width 17.1%
- SMA 50 / 200
- 95.97 / 84.57
- mixed trend
- MACD (12, 26, 9)
- -0.41 / 0.88
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −17.4% | −1.1% | −16.3 pp | — |
| 3 months | −12.3% | −0.5% | −11.8 pp | — |
| 6 months | +3.8% | +4.4% | −0.6 pp | — |
| Year to date | +5.4% | +12.3% | −6.9 pp | — |
| 1 year | +11.6% | +13.5% | −1.9 pp | +0.8% |
| 3 years | −19.6% | +76.4% | −96.0 pp | −49.7% |
| 5 years | −14.1% | +63.7% | −77.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 466.8 m | 440.8 m | 439.7 m | 441.9 m | 455.6 m | 453.2 m | 491.4 m | 473.6 m |
| Cost of revenue | 330.6 m | 315.7 m | 316.5 m | 325.2 m | 328.2 m | 329.7 m | 353.1 m | 344.5 m |
| Gross profit | 136.2 m | 125.1 m | 123.2 m | 116.7 m | 127.4 m | 123.5 m | 138.3 m | 129.1 m |
| Research & development | 14.9 m | 12.7 m | 13.6 m | 13.7 m | 11.0 m | 13.2 m | 14.2 m | 16.8 m |
| SG&A | 78.9 m | 69.3 m | 74.6 m | 71.9 m | 69.3 m | 78.5 m | 84.3 m | 71.7 m |
| Operating income | 41.1 m | 42.5 m | 34.3 m | 5.9 m | 46.8 m | 36.5 m | 39.7 m | 41.7 m |
| Depreciation & amortisation | 10.9 m | 10.9 m | 11.1 m ≈ | 12.2 m ≈ | 9.4 m | 9.9 m | 10.0 m ≈ | 9.6 m ≈ |
| Pre-tax income | -102.6 m | 45.2 m | 32.3 m | 11.3 m | 49.3 m | 39.9 m | 41.6 m | 42.6 m |
| Income tax | -32.2 m | 11.6 m | 8.4 m | -1.4 m | 2.9 m | 9.1 m | 10.4 m | 11.0 m |
| Net income | -70.4 m | 32.8 m | 23.5 m | 12.9 m | 47.4 m | 30.4 m | 30.8 m | 31.8 m |
| Diluted EPS | -2.80 ≈ | 1.31 | 0.94 | 0.52 | 1.91 ≈ | 1.22 | 1.25 | 1.29 |
| Operating cash flow | 25.7 m | 28.3 m | 10.5 m ≈ | 39.1 m ≈ | 60.4 m | 17.6 m | 7.2 m ≈ | 17.4 m ≈ |
| Dividends paid | 19.8 m | — | — | 0 ≈ | 21.6 m | — | — | 0 ≈ |
| Share repurchases | 0 | 4.8 m | 8.5 m ≈ | 10.6 m ≈ | 0 | 7.1 m | 6.4 m ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 39-quarter history (min 14.7, median 21.7, max 138.8; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5 bn | 1.5 bn | 1.2 bn | 1.5 bn | 2.0 bn | 1.9 bn | 1.8 bn | 1.8 bn |
| Revenue YoY | +13.0% | +2.5% | −21.2% | +24.3% | +32.4% | −0.8% | −5.3% | −3.7% |
| Net income | 85.0 m | 112.2 m | 28.7 m | 93.1 m | 133.0 m | 139.1 m | 35.6 m | 116.6 m |
| Net income YoY | +37.5% | +32.0% | −74.4% | +224.4% | +42.9% | +4.6% | −74.4% | +227.5% |
| Diluted EPS | 3.45 | 4.54 | 1.16 | 3.75 | 5.32 | 5.56 | 1.42 | 4.67 |
| Diluted EPS YoY | +36.9% | +31.6% | −74.4% | +223.3% | +41.9% | +4.5% | −74.5% | +228.9% |
| net % | 5.8% | 7.4% | 2.4% | 6.3% | 6.8% | 7.1% | 1.9% | 6.6% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 292.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 1.3 bn USD
- Total assets
- 1.8 bn USD
- Debt / equity
- unavailable
- Current ratio
- 2.79x
- ROE
- 9.1%
- ROA
- 6.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.2 bn | 1.5 bn | 2.0 bn | 1.9 bn | 1.8 bn | 1.8 bn | SEC (XBRL)· 18 Feb 2026verified |
| Cost of revenue | 850.4 m | 1.0 bn | 1.4 bn | 1.4 bn | 1.3 bn | 1.3 bn | SEC (XBRL)· 18 Feb 2026verified |
| Gross profit | 342.7 m | 434.9 m | 586.7 m | 591.1 m | 542.9 m | 492.4 m | SEC (XBRL)· 18 Feb 2026verified |
| Research & development | 30.9 m | 37.4 m | 38.7 m | 49.0 m | 56.5 m | 51.0 m | SEC (XBRL)· 18 Feb 2026verified |
| SG&A | 237.0 m | 267.2 m | 360.7 m | 380.5 m | 305.3 m | 285.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Operating income | 33.7 m | 132.1 m | 187.3 m | 161.6 m | 177.9 m | 129.5 m | SEC (XBRL)· 18 Feb 2026verified |
| Depreciation & amortisation | 46.0 m | 42.7 m | 40.1 m | 39.3 m | 43.5 m | 43.6 m | SEC (XBRL)· 18 Feb 2026verified |
| EBITDA | 79.7 m ≈ | 174.8 m ≈ | 227.4 m ≈ | 200.9 m ≈ | 221.4 m ≈ | 173.1 m ≈ | SEC (XBRL)· 18 Feb 2026derived |
| Interest expense | 800.0 k | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 18 Feb 2026verified |
| Pre-tax income | 39.7 m | 134.4 m | 184.6 m | 174.4 m | 41.2 m | 138.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Income tax | 11.0 m | 41.3 m | 51.6 m | 35.3 m | 5.6 m | 21.5 m | SEC (XBRL)· 18 Feb 2026verified |
| Net income | 28.7 m | 93.1 m | 133.0 m | 139.1 m | 35.6 m | 116.6 m | SEC (XBRL)· 18 Feb 2026verified |
| Diluted EPS | 1.16 | 3.75 | 5.32 | 5.56 | 1.42 | 4.67 | SEC (XBRL)· 18 Feb 2026verified |
| Weighted average diluted shares | 24.8 m | 24.9 m | 25.0 m | 25.0 m | 25.1 m | 25.0 m | SEC (XBRL)· 18 Feb 2026verified |
| Dividend per share | 1.04 | 1.16 | 1.28 | 1.41 | 1.55 | 1.71 | SEC (XBRL)· 18 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 105.3 m | 141.8 m | 147.1 m | 203.7 m | 289.2 m | 292.5 m | SEC (XBRL)· 18 Feb 2026verified |
| Inventories | 220.0 m | 277.6 m | 373.1 m | 300.1 m | 301.0 m | 329.3 m | SEC (XBRL)· 18 Feb 2026verified |
| Current assets | 566.2 m | 728.1 m | 872.6 m | 885.7 m | 956.6 m | 1.0 bn | SEC (XBRL)· 18 Feb 2026verified |
| Property, plant & equipment, net | 210.8 m | 214.4 m | 220.9 m | 268.3 m | 269.7 m | 286.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Goodwill | 371.2 m | 364.3 m | 358.8 m | 399.3 m | 382.5 m | 399.0 m | SEC (XBRL)· 18 Feb 2026verified |
| Intangibles (excl. goodwill) | 75.3 m | 57.5 m | 45.0 m | 57.3 m | 65.4 m | 67.7 m | SEC (XBRL)· 18 Feb 2026verified |
| Total assets | 1.4 bn | 1.6 bn | 1.6 bn | 1.7 bn | 1.7 bn | 1.8 bn | SEC (XBRL)· 18 Feb 2026verified |
| Accounts payable | 98.7 m | 148.7 m | 165.3 m | 163.6 m | 163.8 m | 174.7 m | SEC (XBRL)· 18 Feb 2026verified |
| Short-term debt | 0 | — | — | — | — | — | SEC (XBRL)· 17 Feb 2021verified |
| Long-term debt | 0 | — | — | — | — | — | SEC (XBRL)· 17 Feb 2021verified |
| Current liabilities | 252.4 m | 336.6 m | 405.8 m | 371.5 m | 371.4 m | 360.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Total liabilities | — | 537.9 m | 563.3 m | 557.8 m | 518.6 m | 499.5 m | SEC (XBRL)· 18 Feb 2026verified |
| Equity | 944.9 m | 1.0 bn | 1.0 bn | 1.1 bn | 1.2 bn | 1.3 bn | SEC (XBRL)· 18 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 145.9 m | 93.2 m | 81.7 m | 207.3 m | 184.5 m | 138.3 m | SEC (XBRL)· 18 Feb 2026verified |
| Investing cash flow | -29.7 m | -36.2 m | -42.1 m | -111.8 m | -62.0 m | -75.1 m | SEC (XBRL)· 18 Feb 2026verified |
| Financing cash flow | -86.8 m | -20.0 m | -33.7 m | -39.0 m | -35.3 m | -63.9 m | SEC (XBRL)· 18 Feb 2026verified |
| Dividends paid | 25.6 m | 28.8 m | 31.7 m | 35.1 m | 38.8 m | 42.4 m | SEC (XBRL)· 18 Feb 2026verified |
| Share repurchases | 2.1 m | 800.0 k | 5.9 m | 1.1 m | 700.0 k | 23.9 m | SEC (XBRL)· 18 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
Risk
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 2.0 bn USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 22.47 – 239.31 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E177.73 – 239.31 (Mid 194.90)3 companies used · median multiple 34.4x · quartiles 31.4x – 42.2xBCPC, NGVT, SOLS
- Dividend discount (DDM)22.47 – 30.22 (Mid 25.78)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 7.5% | 86 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -3.3% | 0 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | -4.3% | 0 (on a fixed band) | 19% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.9x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | 14.2x | 72 (on a fixed band) | 24% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 2.9% | 42 (on a fixed band) | 14% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality· partial86/100 · 1/3 factors with a value
- Returns· partial42/100 · 1/2 factors with a value
- Valuation· partial72/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
INNOSPEC INC. (IOSP). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 1.8 bn USD in 2025; YoY growth -3.7%; net margin 7.5%; ROE 10.5%.
The estimated value range is 100.10–134.77 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 110.34 USD, the price of 80.65 USD leaves a potential of 36.8% (value / price − 1) and a margin of safety of 26.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 7.5%
- Current ratio: 2.9x
- P/E (TTM): 14.2x
- The price is below the estimated value range
What contradicts it
- Revenue CAGR 3Y: -3.3%
- EPS CAGR 3Y: -4.3%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Net debt / EBITDA, Interest coverage, EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Chemicals & Allied Products (SIC 2800) · same industry (4-digit SIC) · compared with 14 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SOLSSolstice Advanced Materials Inc. | 9.1 bn | 28.3 | 13.6% | 7.8% | +3.1% | +21% / unavailable |
| BCPCBalchem Corporation | 5.8 bn | 34.4 | 13.0% | 15.4% | +8.8% | +17% / +46% |
| PRMPerimeter Solutions, Inc. | 4.6 bn | — | -30.9% | -44.9% | +16.4% | +1% / +575% |
| NGVTIngevity Corporation | 2.5 bn | 50.1 | 64.4% | 4.7% | −2.7% | +41% / +90% |
| CCThe Chemours Company | 2.1 bn | — | -339.7% | -5.2% | +0.4% | +8% / −50% |
| OLNOlin Corporation | 2.1 bn | — | -12.2% | -3.3% | +3.7% | −14% / −62% |
| IOSPInnospec Inc. | 2.0 bn | 14.2 | 10.5% | 7.5% | −3.7% | +12% / −20% |
| HUNHuntsman Corporation | 1.7 bn | — | -11.8% | -5.8% | −5.8% | −5% / −60% |
| ECVTEcovyst Inc. | 1.1 bn | — | -9.6% | -7.1% | +20.9% | +8% / +5% |
| FMCFmc Corporation | 998.7 m | — | -226.7% | -151.2% | −18.3% | −55% / −88% |
| ACNTAscent Industries Co. | 124.0 m | — | -1.1% | -1.0% | −7.2% | −3% / +68% |
| CITRCitroTech Inc. | 54.8 m | — | -431.0% | -1,788.4% | +194.6% | unavailable / unavailable |
| LOOPLoop Industries, Inc. | 13.0 m | — | — | -2,154.3% | −95.3% | −77% / −92% |
| GUREGulf Resources, Inc. | 5.6 m | — | -32.4% | -134.4% | +231.8% | +3% / −80% |
| ADURAduro Clean Technologies Inc. | — | — | -133.8% | -5,253.1% | −31.5% | −26% / unavailable |
1- and 3-year price returns: for IOSP from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 44.20 Total return -44% · Per year -44% | 78.46 Total return -1% · Per year -1% | 118.61 Total return 50% · Per year 50% |
| 3 years | 36.47 Total return -51% · Per year -21% | 73.43 Total return -3% · Per year -1% | 122.78 Total return 60% · Per year 17% |
| 5 years | 30.09 Total return -56% · Per year -15% | 68.73 Total return -5% · Per year -1% | 127.10 Total return 71% · Per year 11% |
- Exit P/E± 18.36
- Net margin± 12.85
- Annual revenue growth± 11.40
- Annual dilution± 1.08
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 10-Q (04 Nov 2026), 8-K (03 Nov 2026 · results).
In brief
Innospec is an international specialty chemicals company with three segments: Performance Chemicals, Fuel Specialties and Oilfield Services. In the second quarter of 2026 total revenues rose 12 percent, and the company remains debt-free with cash of over 250 million dollars, giving it flexibility in an uneven market.
SWOT
Strengths
- The company has a solid financial position, with no debt and substantial cash, giving it flexibility for investment and acquisitions 12.
- Fuel Specialties has stable margins and rising operating income, supported by innovation and independence from major oil companies 1.
- Its technology base and intellectual property are considered competitive advantages across all segments 1.
Weaknesses
Opportunities
- Expansion of the DRA plant and a recovery in Middle East activity could support Oilfield Services growth 13.
- Sulfate-free and 1,4-dioxane-free personal and home care products could open new markets in Performance Chemicals 1.
- Non-fuel applications of fuel technologies could widen the addressable market for Fuel Specialties 1.
Risks
- Competition and market conditionsmedium
Larger competitors can adapt more easily and may cut prices, which could reduce the company's market share 1.
- International operationshigh
Political instability, tariffs and restrictions on repatriation of earnings in unstable regions could affect results 1.
- Acquisitions and integrationmedium
Integrating acquisitions could bring unexpected costs and absorb financial and management resources 1.
- Cyber security and ERP implementationhigh
Cyber attacks and problems in the new ERP rollout could disrupt operations and reporting 1.
- Environmental liabilities and plant closuresmedium
Plant closure provisions, mainly at Ellesmere Port in the UK, could change materially if estimates shift 1.
Investment thesis
What would need to be true (bull case)
- The company has a debt-free balance sheet and substantial cash, leaving room for growth, dividends and share buybacks 12.
- Fuel Specialties shows steady growth in operating income, and emissions rules could support long-term demand 13.
- A recovery in Performance Chemicals margins and growth in Oilfield Services after the DRA expansion could accelerate growth in the second half of 2026 23.
What would break the thesis
- Performance Chemicals margins fell in 2025 and in the second quarter of 2026, which could signal that pricing pressure persists 12.
- Oilfield Services depends on oil and gas activity in a few regions, and the lack of recovery in Latin America could limit growth 1.
- Phasing out leaded aviation fuel could gradually reduce AvGas sales, and the company has no clear alternative for this product 1.
What to watch
- Performance Chemicals margin trend and the effect of pricing and productivity actionsQ3 2026
- Recovery of operating cash flow through better working capital efficiency2026
- Oilfield Services activity after the DRA plant expansion and Middle East recovery2026
- Progress of aviation lead phase-out rules and their impact on the AvGas linenext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 10-Q (04 Nov 2026), 8-K (03 Nov 2026 · results).
The business
Innospec develops, manufactures, blends and supplies a wide range of specialty chemicals to customers in the Americas, Europe, the Middle East, Africa and Asia-Pacific 1. The Performance Chemicals segment offers technology-based solutions for personal care, home care, agrochemical, construction and mining markets 1. Fuel Specialties manufactures fuel additives that improve efficiency, boost engine performance and reduce emissions 1.
Oilfield Services supplies chemicals for drilling, completion and production, as well as drag reducing agents (DRA) for oil and gas operations 1. The strategy focuses on new and improved products and on acquisitions and partnerships that extend the technology base, geographic reach or portfolio 1. The company says it concentrates on areas where it has experience, which could reduce operating risk 1.
The company is also rolling out a new company-wide ERP platform in phases across several sites 1. It does not depend on any single patent or trademark, but its intellectual property is an important part of its competitive advantage 1.
Segments
Performance Chemicals
In 2025 the segment generated 681.4 million dollars of net sales, up year on year, but margins fell on pricing pressure and a weaker product mix 1. In the second quarter of 2026 revenues reached 190.3 million dollars and operating income rose 15 percent 23.
Fuel Specialties
This is the most stable segment, with net sales of 701.5 million dollars in 2025 and operating income up 12 percent 1. According to the filings, the company is the world's only producer of tetra ethyl lead for aviation gasoline, a product line exposed to regulation aimed at eliminating lead 1.
Market context
The specialty chemicals market is fragmented in Performance Chemicals and concentrated in Fuel Specialties, where there are few competitors and none is dominant 1. Oilfield Services depends on drilling and production activity, which varies by region 1. The company notes that EU REACH and similar regimes in other countries raise testing and registration costs 1.
The fuel market is influenced by fuel quality legislation and the shift to alternative propulsion, factors that could change demand for additives 1. Raw material prices, such as ethylene, can affect costs because one German operation relies on a single source 1.
Trends
- Emissions and fuel regulationtailwind
Tighter global emissions and fuel quality rules support demand for Fuel Specialties additives, particularly for efficient engines and renewable fuels 1.
- Phase-out of leaded aviation fuelheadwind
The EAGLE program aims to eliminate lead emissions from general aviation in the US by the end of 2030, which could reduce sales of the AvGas line 1.
- Oil and gas drilling and completion activitymixed
Drilling and production activity in the Middle East, the US and Latin America drives Oilfield Services revenue, and the company does not expect Latin American production to resume in 2026 1.
- Inflation and energy costsheadwind
Rising wages and energy costs could pressure plant margins, particularly in Performance Chemicals where margins have already declined 12.
Competitive position
In Performance Chemicals competition is intense, with a large number of multinational and specialty suppliers in each region, and larger competitors may have more resources 1. In Fuel Specialties there are few competitors and none is dominant, and Innospec's edge lies in technical capacity and independence from major oil companies 1.
In Oilfield Services a small number of very large competitors sits alongside many smaller players focused on specific technologies or regions, making the market fragmented 1. The company's strengths are its proven technology, broad regional coverage and strong customer relationships 1.
- Multinational personal care and industrial chemical suppliers
The filings do not name individual competitors; the competition comes from the large number of global suppliers in each market 1.
- Fuel additive producers
The segment has a small number of competitors, none dominant, with no names given in the source 1.
- Large oilfield service providers
Among Oilfield Services competitors are a few very large players, not named in the source documents 1.
- Smaller companies specialising in technologies or regions
A large number of smaller suppliers focus on specific technologies or regions 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Innospec’s (IOSP) Strong Quarter Hides A Cash Flow Problem Worth WatchingYahoo Finance — News · 03 Sept 2026 · EN
The latest news item in our archive is from 03 Sept 2026; the newest SEC filing is from 04 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report04 Nov 2026
- Current report03 Nov 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report04 Jun 2026Departure or appointment of officers
- Current report13 May 2026Shareholder vote
- Quarterly report08 May 2026
- Current report08 May 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Proxy statement26 Mar 2026
- Annual report18 Feb 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Innospec Inc. · 18 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Innospec Inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Innospec Inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.